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 i g  h  l  i  g  h  t  s
In the  present  study,  we study  what  doses  can  determines  direct  cardiotoxic  effects  of 5-ﬂuorouracil  on rat  cardiocytes.
We  have  found  that  5-FU  induced  50%  growth  inhibition  at  72  h with  concentrations  of  400  M on  H9c2  cardiocytes.
We  have  found  that  the  addition  of Levofolinic  Acid  (LF)  to 5-FU  potentiated  the  growth  inhibition  induced  by 5-FU.
The  growth  inhibition  induced  by  5-FU  alone  or in combination  with  LF in  cardiocytes  was  paralleled  by an increase  of  Tbars  and end  products  of  NO.
Our data  suggest  that  5-FU  can also  induce  cardiocyte  damage  by oxidative  stress.
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a  b  s  t  r  a  c  t
Fluoropyrimidines  are  key  agents  for the  treatment  of gastrointestinal  tract  adenocarcinomas.  The  pos-
sible  cardiotoxic  effects  in patients  and  occupationally  exposed  workers  are  multifactorial  and  remain
a  puzzle  to solve  for investigators.  In the present  study,  we  study  what  cell  death  pathways  and  what
doses  can determine  direct  cardiotoxic  effects of 5-ﬂuorouracil  (5-FU)  and doxorubicin  (DOXO)  on  rat
cardiocytes  (H9c2)  and  a human  colon  adenocarcinoma  (HT-29)  cell  line,  already  reported  to  be  sensitive
to  5-FU.  We  have  found  that  5-FU  induced  50%  growth  inhibition  (IC:50)  at 72 h with  concentrations
of  400  M and  4 M on H9c2  and  HT-29,  respectively.  Moreover,  we  have  found  that  the addition  of
Levofolinic  Acid  (LF)  to 5-FU  potentiated  the  growth  inhibition  induced  by 5-FU.  The  growth  inhibition
induced  by  5-FU  alone  or in combination  with  LF in cardiocytes  was  paralleled  by  an  increase  of thio-
barbituric  acid-reactive  species  (Tbars)  and  end  products  of  nitric  oxide  (NO)  suggesting  the increase  of
the oxidative  stress  status  in  cardiocytes.  Interestingly,  these  effects  were  strongly  potentiated  by  the
addition  of LF, a biochemical  modulator  of  5-FU activity.
Our  data  suggest  that  agents  such  as  5-FU  different  from  anthracyclines,  conventionally  related  to the
induction  of cardiotoxic  effects,  can  also  induce  cardiocyte  damage  paralleled  by  oxidative  stress.  The
strategies  based  upon  the  use  of scavengers  could  be  used  in order  to  prevent  this  effect.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
More than two decades after its synthesis (Duschinsky et al.,
957), 5-ﬂuorouracil (5-FU) remains a key agent to several
hemotherapy regimens, particularly for the treatment of gastroin-
estinal tract adenocarcinomas in combination with levofolene (LF)
Ashraf et al., 2013; Rödel et al., 2012). On these bases, there is no
eason in studying 5-FU effect without combining it with LF.
∗ Corresponding author. Tel.: +39 0815665901; fax: +39 0815665901.
E-mail address: monicalamberti@libero.it (M.  Lamberti).
ttp://dx.doi.org/10.1016/j.toxlet.2014.03.018
378-4274/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open acce
y-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Unfortunately, like most chemotherapeutic agents, 5-FU alone
or, more markedly, in combination with LF has also numerous
toxic effects as diarrhea, mucositis, myelosuppression, and throm-
bophlebitis of peripheral veins (Sorrentino et al., 2012). The wide
range of cardiotoxicity related to 5-FU occurs less frequently but
are typically more serious. The most severe cardiac complications
are heart failure (Brestescher et al., 1995), arhythmia (Weidmann
et al., 1995; Eskilsson et al., 1988; Aziz et al., 1998) and myocardial
ischemia (Gorgulu et al., 2002).
This risk is also possible in the healthcare workers during the
phases of manipulation of antiblastic drugs. In fact, several scientiﬁc
studies have shown that workers can be exposed to cardiotoxic
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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rugs such as doxorubicin, epirubicin, cyclophosphamide and 5-FU
Connor et al., 2010; Lamberti et al., 2014).
The understanding of the molecular mechanisms at the basis of
he cardiotoxic effects of 5-FU could be useful in order to determine
ossible pharmacological strategies in order to prevent this dele-
erious side effect. Moreover, studies on the toxic effects of 5-FU
lone or in combination with LF on in vitro models of cardiocytes
re presently limited. In this view, the setting of an experimental
odel in which the molecular mechanisms of toxicity can be easily
tudied could be useful in order to detect new targets and strategies
o prevent cardiac side effects of anti-cancer agents without reduc-
ng their anti-cancer activity. The availability of a cheap cardiac
n vitro model for the study of the molecular pathways disrupted
y the treatment with 5-FU could be a useful tool to ﬁnd new tar-
ets to be validated in a preclinical in vivo model. In fact, it is not
till clear how to correctly study in preclinical and clinical model
he occurrence of the molecular events of 5-FU-induced cardiotox-
city and therefore the cardiopreventive approaches are still a black
ole.
The following different mechanisms of the cardiac toxic effect
nduced by 5-FU have been proposed: coronary artery spasm,
utoimmune-mediated injury of the myocardium, endothelial
amage, thrombogenic effects or thrombus formation, global
ysfunction, accumulation of metabolites and direct myocardial
oxicity causing necrosis (Sorrentino et al., 2012).
In the present manuscript, we have studied the concentrations
f 5-FU and doxorubicin (DOXO) that can determine direct car-
iotoxic effects in a model of rat cardiocytes (H9c2). Moreover,
e have studied the oxidative stress changes and the mitochon-
rial membrane potential transition in order to ﬁnd biochemical
orrelates to the cardiac damage.
. Materials and methods
.1. Materials
RPMI, DMEM,  and FBS were purchased from Flow Laboratories (Milan, Italy).
issue culture plasticware was from Microtech (Naples, Italy).
.2. Cell culture and proliferation
The rat cardiocytes (H9c2) cell line and the human colon
denocarcinoma (HT-29) cell line obtained from the American
ype Tissue Culture Collection, Rockville, MD,  grow in DMEM and
PMI1640, respectively, supplemented with heat inactivated 10%
BS, 20 mM HEPES, 100 U/ml penicillin, 100 mg/ml  streptomycin,
% l-glutamine and 1% sodium pyruvate. Both cell lines were grown
n a humidiﬁed atmosphere of 95% air, 5% CO2 at 37 ◦C. Prolifera-
ion of H9c2 and HT-29 cell lines was performed in the presence of
-FU (2–1250 M),  alone and in combination with 10−4 M of Levo-
olene (LF), and of DOXO (0.1–6.4 M),  by MTT  assay as previously
escribed (Chiosi et al., 2007).
.3. Nitrite assay
NO is rapidly converted into the stable end products nitrite
NO2−) and nitrate. Nitrite was measured by the Griess reaction
s previously reported (Titheradge, 1998). The nitrite assay used in
his work was described in Gomez-Monterrey et al. (2013).
.4. Thiobarbituric acid-reactive species (Tbars) levelsSamples were incubated with 0.5 ml  of 20% acetic acid, pH
.5 and 0.5 ml  of 0.78% aqueous solution of thiobarbituric acid.
fter heating at 95 ◦C for 45 min, the samples were centrifuged
t 4000 rpm for 5 min. In the supernatant fractions Tbars weretters 227 (2014) 151–156
quantiﬁed by spectrophotometry at 532 nm (Gomez-Monterrey
et al., 2013). Results were expressed as Tbars M/g of serum pro-
tein. Each data point is the average of triplicate measurements, with
each individual experiment performed in duplicate as previously
reported in Caraglia et al., 2011.
2.5. Determination of mitochondrial potential through FACS
analysis (MitoTracker Red)
After 24, 48 and 72 h from the beginning of the established treat-
ments cells were detached, centrifuged at 1200 × g for 5 min and
resuspended in PBS. MitoTracker Red probe was added at a ﬁnal
concentration of 100 nM.  The latter does not emit ﬂuorescence
if it is not internalized in living cells. Once in the cytoplasm of
living cells the probe is oxidized in a series of reactions in pres-
ence of ROS and if mitochondrial pores are opened due to the
mitochondrial potential transition, the probe enters into the mito-
chondria. The positively charged probe binds the mitochondrial
proteins and emits a red ﬂuorescence. After the incubation with
the probe for 20 min  at room temperature in the dark, cells were
centrifuged, resuspended and analysis of red ﬂuorescence was  per-
formed by ﬂow cytometry (FACScan, Becton Dickinson). For each
sample, 2 × 104 events were acquired. Analysis was  carried out by
triplicate determination on at least three separate experiments.
2.6. Statistical analysis
All data are expressed as mean ± SD. Statistical analysis was
performed by analysis of variance (ANOVA) with Neumann–Keul’s
multiple comparison test or Kolmogorov–Smirnov where appro-
priate.
3. Results
3.1. Effects of DOXO and 5-FU on H9c2 and HT-29 on cell
proliferation
We  studied the effect of increasing concentrations of DOXO and
5-FU in presence or not of LF on growth inhibition of HT-29 and
H9c2 cells by MTT  assay as described in Section 2. We have found
a dose and time-dependent (data not shown) growth inhibition
in both cell lines. The IC:50 (50% inhibitory concentration) was
reached after 72 h by pharmacological treatment in both cell lines.
In details, the values of 5-FU were 4 M and 400 M in HT-29 and
H9c2, respectively, after 72 h from the beginning of the treatment
(Fig. 1). Moreover, LF potentiated growth inhibition induced by 5-
FU. In fact, IC:50 of HT-29 and H9c2 cells was  2 M and 43 M,
respectively, (Fig. 1).
These results suggest, as expected, that the colon cancer cell line
HT-29 was more sensitive to 5-FU than H9c2 normal cells (Fig. 1).
Interestingly, these concentrations of 5-FU can be reached in vivo
after the routinely used ways of administration of this agent in the
clinical practice (Büchel et al., 2013).
On the other hand, H9c2 cells appeared to be more sensitive
to DOXO than HT-29. In fact, the IC:50 of DOXO was  0.12 M and
0.31 M on H9c2 and HT-29, respectively, (Fig. 1).
3.2. Effects of 5-FU ± LF on peroxidation of membrane lipids and
NO2− formation
In order to evaluate the oxidative stress in cardiocytes and in
human colon adenocarcinoma cells treated with the different anti-
cancer agents, we have assessed the intracellular Tbars in order to
add data about the membrane lipid peroxidation. Tbars levels were
almost undetectable in untreated cardiocytes while the treatment
of the cells with 400 M of 5-FU for 72 h induced the formation
M. Lamberti et al. / Toxicology Letters 227 (2014) 151–156 153
Fig. 1. Antiproliferative effects of 5-FU and/or LF or DOXO on H9c2 and HT-29 cells. The
cells were seeded and treated with different concentrations of 5-FU or 5-FU + LF or
DOXO for 72 h and thereafter the cell growth inhibition was evaluated with viability
MTT  assay as described in Section 2. Thereafter, the concentration of the different
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Fig. 3. Effects of 5-FU and/or LF on Tbars in HT-29 cells. The cells were seeded in six
multi-well plates at the density of 15 × 104 cells/plate and, after attachment, they
were incubated with 5-FU alone and in combination with LF for 72 h, as described
in  the text. Tbars levels in the different experimental conditions were determinedrugs inducing 50% growth inhibition (IC:50) after 72 h of treatment was  calculated
nd  expressed in columns. The experiments were performed three different times.
he bars represent means ± SD of three independent experiments.
f about 1.1 M/g of proteins of Tbars (Fig. 2). Interestingly, the
xposure of cardiocytes to 43 M of 5-FU in combination with
0−4 M of LF caused the formation of about 6.6 M/g of proteins of
bars thus potentiating the effects induced by 5-FU alone (Fig. 2).
n the other hand, Tbars levels in human colon adenocarcinoma
ells treated with 4 M of 5-FU for 72 h were about 0.015 M/g
f proteins of Tbars while the treatment of the cells with 2 M of 5-
−4U in combination with 10 M of LF resulted in a smaller increase
f Tbars levels with 0.017 M/g of proteins of Tbars (Fig. 3). In the
ame experimental conditions, we have also evaluated the forma-
ion of NO2− in the cell medium. We  have found that NO2− levels
ig. 2. Effects of 5-FU and/or LF on Tbars in H9c2 cardiomyocytes. The cells were seeded
n  six multi-well plates at the density of 25 × 104 cells/plate and, after attachment,
hey were incubated with 5-FU alone and in combination with LF, as described in
he text, for 72 h. Tbars levels in the different experimental conditions were deter-
ined as described in Section 2. The bars represent means ± SD of three independent
xperiments. Asterisks indicate signiﬁcant difference between 5-FU-treated vs. 5-
U  + LF-treated cells (** P < 0.003) and untreated vs. 5-FU-treated cells (* P < 0.05).as  described in Section 2. The bars represent means ± SD of three independent
experiments. Asterisks indicate signiﬁcant difference between 5-FU-treated vs. 5-
FU  + LF-treated cells (**P < 0.003) and untreated vs. 5-FU-treated cells (* P < 0.05).
were about 0.9 nM/g proteins in untreated cardiocytes while the
treatment of the cells with 400 M of 5-FU for 72 h induced the
formation of about 2.0 nM/g proteins of NO2− (Fig. 4). Again, the
exposure of cardiocytes to 43 M of 5-FU in combination with
10−4 M of LF potentiated the formation of NO2− that reached a value
of about 8.3 nM/g proteins suggesting a potentiation of the com-
bination on the secretion of potentially detrimental agents for heart
function such as NO2− (Fig. 4). On the other hand, NO2− levels in
untreated colon adenocarcinoma cells were 0.017 nM/g proteins
while the treatment with 4 M of 5-FU for 72 h induced a decrease
in the formation of NO2− with 0.009 nM/g proteins (Fig. 5). The
treatment with 2 M of 5-FU and 10−4 M of LF caused an additional
decrease of NO2− levels reaching about 0.005 nM/g proteins of
Fig. 4. Effects of 5-FU and/or LF on NO−2 secretion in H9c2 cardiomyocytes. The cells
were seeded in six multi-well plates at the density of 25 × 104 cells/plate and, after
attachment, they were incubated with 5-FU alone and in combination with LF, as
described in the text, for 72 h. NO2- levels in the different experimental conditions
were determined in the cell medium as described in Section 2. The bars represent
means ± SD of three independent experiments. Asterisks indicate signiﬁcant differ-
ence  between 5-FU-treated vs. 5-FU + LF-treated cells (** P < 0.003) and untreated vs.
5-FU-treated cells (* P < 0.05).
154 M. Lamberti et al. / Toxicology Le
Fig. 5. Effects of 5-FU and/or LF on NO2− secretion in HT-29 cells. The cells were
seeded in six multi-well plates at the density of 15 × 104 cells/plate and, after
attachment, they were incubated with 5-FU alone and in combination with LF for
72 h, as described in the text. NO2− levels in the different experimental conditions
were determined in the cell medium as described in Section 2. The bars represent
means ± SD of three independent experiments. Asterisks indicate signiﬁcant differ-
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bnce between 5-FU-treated vs. 5-FU + LF-treated cells ( P < 0.003) and untreated vs.
-FU-treated cells (* P < 0.05).O2− (Fig. 5). These data suggested that adenocarcinoma cells were
ess sensitive to damage induced by pharmacological treatments on
eroxidation of membrane lipids compared to cardiocytes probably
ecause of their tumor histogenesis.
ig. 6. Analysis of the mitochondrial membrane potential in cells treated with 5-FU and/or LF 
f  5-FU or 5-FU + LF or DOXO corresponding to their respective IC:50s for 24 h (A), 48 h (
erformed after MitoTracker labelling as described in Section 2. CTR− indicates untreate
itoTracker. The MFI  changes have been evaluated as percentage of CTR+ and were repre
ars  represent means ± SD of three independent experiments.tters 227 (2014) 151–156
3.3. Effects of 5-FU ± LF on mitochondrial membrane potential
Effects of either 5-FU, alone or in combination with LF, or of
DOXO on membrane mitochondrial potential of H9c2 cells was
evaluated through FACS analysis after MitoTracker labelling as
described in Section 2. The ﬂuorescence intensity was quantized
at FACS and expressed as Mean Fluorescence Intensity (MFI) in
percentage of positive control.
After 24 h form the beginning of the treatment 5-FU alone
induced an about 40% increase of MFI  and this effect was not
changed by the addition of LF while DOXO caused an about 80%
increase of MFI  (Fig. 6). After 48 h, 5-FU alone induced an about
50% increase of MFI  that was potentiated by the addition of LF
(about 83% MFI  increase). In the same experimental conditions,
DOXO caused an about 120% increase of MFI  (Fig. 6).
After 72 h from the beginning of the treatment, the ﬂuorescence
levels in cells exposed to 5-FU with or without the addition of
LF resumed to those of untreated cells while DOXO-treated cells
showed still an about 60% increase of MFI  if compared to untreated
cells. Interestingly, LF alone did not induce relevant changes in MFI
in all the time points evaluated in our experimental conditions
(Fig. 6).
4. Discussion
Incidence of cardiotoxicity in patients treated with 5-FU varies
between 1.2 and 18% with a mortality rate between 2.2 and 13.3%
(Burger and Mannino, 1987; Teixeira et al., 2004; Meyer et al.,
1997). The appearance of toxic effects is also possible in exposed
workers, because 5-FU has been reported as one of the more con-
centrated chemotherapeutic drug in the work areas (950 ng/cm2)
(Connor et al., 2010). Yoshida et al. (2011) showed that, in
or DOXO on H9c2 cardiocytes. The cells were seeded and treated with concentrations
B) or 72 h (C) and then the analysis of the mitochondrial membrane potential was
d cells not labelled with MitoTracker; CTR+ indicates untreated cells labelled with
sented as columns (D). The experiments were performed at least three times. The
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 hospitals in Japan, 5-FU had the highest concentration detected
n working table, on ﬂoor and in air-conditioner ﬁlter (respectively,
3 ± 44 ng/m2; 5.2 ± 4.2 ng/m2 and 4600 ng).
Extensive studies of biological monitoring, in exposed workers,
or 5-FU have not been made and therefore it is not possible to
ssess accurately the level of exposure of the medical staff; how-
ver, other toxic effects more easily correlated with the exposure
uch as myelosuppression and hepatic toxicity have already been
ighlighted in a population of 5800 workers (Caciari et al., 2012).
Although mortality is also uniformly higher in subjects with
nderlying heart disease, including coronary artery disease (CAD),
tructural heart disease, and cardiomyopathies (Labianca et al.,
982; Rezkalla et al., 1989), the mechanism of cardiotoxicity of 5-FU
emains poorly deﬁned.
The main cause of identiﬁed cardiotoxicity is a direct effect
n vascular endothelium that involves endothelial nitric oxide
NO) synthase and leads to coronary spasms and endothelium-
ndependent vasoconstriction via protein kinase pathway. The
auses of these responses are not clear but are independent from
asoactive cell membrane receptors, phosphoinositide turnover,
r activation of the cyclooxygenase (Luwaert et al., 1991; Mosseri
t al., 1993; Shoemaker et al., 2004; Sudhoff et al., 2004).
However, in contrast to this theory there is no evidence that
alcium channel blockers or nitrates reduce the risk of cardiotoxi-
ity (Patel et al., 1987; Eskilsson and Albertsson, 1990). These data
uggest that there are other mechanisms of cardiotoxicity.
De Forni et al. (1992) suggested the possibility of a direct drug
oxic action on the myocardium, particularly giving evidence that
here is global systolic dysfunction, which does not correspond to
ny individual coronary artery territory.
The intravenous bolus and the continuous administration
odalities of 5-FU are both cardiotoxic even if the mechanism of
eart toxicity is different. It has to be considered that acute toxic-
ty on bone marrow and gastro-intestinal tract is certainly reduced
ith the continuous infusion modality (Arkenau et al., 2005). About
he cardiotoxicity, Tsibiribi et al. (2006) showed that rabbits receiv-
ng bolus 5-FU developed massive hemorrhagic myocardial infarcts
ith evidence of proximal coronary vasospasm. However, animals
reated with repeated low 5-FU doses had heart histologic changes
onsistent with toxic myocarditis together with the occurrence
f apoptosis. These data together with large circadian changes of
ss (3–25 times) of intravenous 5-FU could justify the wide vari-
tion of cardiotoxicity induced by 5-FU in patients. It has also to
e considered that it has been reported an increased incidence
f cardiac-related events in patients with continuous 24-h 5-FU
nfusion for 5 days rather than in patients with short 5-FU admin-
stration (Diasio and Harris, 1989; Kosmas et al., 2008; Tsavaris
t al., 2005). Therefore, the continuous infusion of 5-FU impacts
ifferently on both cardiotoxicity and general side effects.
In our study, we have shown that 5-FU induced 50% growth inhi-
ition (IC:50) at 72 h with concentrations of 400 M and 4 M on
9c2 and HT-29, respectively. Moreover, we have found that the
ddition of LF to 5-FU potentiated the growth inhibition induced
y 5-FU reaching an IC:50 of about 43 M on H9c2. These concen-
rations are clinically relevant since the serum levels reached by
-FU vary from 0.1 to 175 M (Büchel et al., 2013). In the present
anuscript, we have also evaluated in H9c2 and HT-29 cells the
ffects of 5-FU on intracellular Tbars levels and on the production
f NO2−, NO terminal product. We have, indeed, found that 5-FU
aused an increase of the peroxidation of membrane lipids with an
ncrease of NO2− levels. However, cardiocytes were more sensitive
o damage induced by pharmacological treatment on peroxidation
f membrane lipids compared to colon adenocarcinoma cells prob-
bly because of their cancer phenotype and different tissue origins.
All these ﬁndings were in agreement with the induction of an
ncrease of the oxidative stress status in cardiocytes. Moreover,tters 227 (2014) 151–156 155
these effects were paralleled with a transition of the mitochon-
drial potential that could be responsible for apoptosis occurrence
as already demonstrated by previous studies (Lamberti et al., 2011).
In fact, although, cardiocytes have protective mechanisms that
overcome the apoptotic injury caused by several toxic agents that
can circulate in the bloodstream, this program probably is not able
to avoid the injury induced by agents with a very high oxidative
potential as some anti-cancer agents. This apoptotic effect could
be due to the induction of the increase of intracellular ROS in
cardiomyocytes exposed to 5-FU ± LF (Lamberti et al., 2012). The
mechanism of cardiomyocytes apoptosis linked to the intracellu-
lar oxidative stress are different: (i) generation of free radicals and
lipid peroxidation of cardiac membranes (Eken et al., 2010), (ii)
myocyte damage induced by cardiac calcium overload (Fucic et al.,
1998), (iii) formation of DOX-iron complex (Favier et al., 2003),
(iv) impaired myocardial adrenergic regulation, cellular toxicity of
anthracycline metabolites (Undeger et al., 1999), and (v) inhibi-
tion of beta-oxidation of long chain fatty acids with the consequent
depletion of cardiac ATP (Maluf and Erdtmann, 2000).
In conclusion, our data suggest that agents such as 5-FU different
from anthracyclines, that are conventionally related to the induc-
tion of cardiotoxic effects, can also induce cardiocyte damage that is
paralleled by oxidative stress. Therefore, strategies based upon the
use of scavengers could be useful in order to prevent this effect. The
data obtained in this study will be conﬁrmed in vivo with a series
of experiments already in preparation. Moreover, we are perform-
ing experiments in order to ﬁnd molecular markers predictive of
cardiac toxicity (such as miRNAs) both in vitro and in a preclinical
model of cardiotoxicity.
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